Skip to main content
S&P 5007,774.34-0.40%DOW51,720.44+0.10%NASDAQ27,041.76-0.60%BTC$82,809.00-0.57%ETH$2,479.55-1.06%GOLD$4,109.20-1.63%OIL$95.47+1.41%
Smart Investors Daily
SID Premium
QT

NASDAQ · QTTB

Q32 Bio Inc.

Healthcare · Biotechnology

$8.06

Down-$0.68 (-7.78%)

Updated Oct 14, 2026, 12:35 PM

SID Score

4.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
39.25M
P/E ratio
-0.93
Dividend yield
0.00%
52-week range
$4.40 – $23.57
Volume
719.98K
Avg. volume
3.07M

Price performance · QTTB

QTTB price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 13, 2026

QTTB closed at $8.06 after 21 trading sessions, down 27.84% for the selected period.

Last close
$8.06
Period change
-27.84%
Period low
$7.99
Period high
$11.17
Daily close
View OHLC price history
QTTB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 13, 2026$8.69$8.69$7.89$8.06719.98K
Oct 12, 2026$8.64$9.155$8.44$8.74684.59K
Oct 9, 2026$8.125$8.46$7.94$8.34854.92K
Oct 8, 2026$7.94$8.12$7.62$8.09860.24K
Oct 7, 2026$8.00$8.07$7.83$7.99570.15K
Oct 6, 2026$8.32$8.36$7.80$8.11678.82K
Oct 5, 2026$8.09$8.56$7.81$8.37955.75K
Oct 2, 2026$8.35$9.11$8.17$8.232.1M
Oct 1, 2026$8.36$8.85$7.75$8.253.09M
Sep 30, 2026$10.40$10.40$7.8775$8.275.25M
Sep 29, 2026$9.32$9.665$9.164$9.53918.14K
Sep 28, 2026$9.21$9.445$8.77$9.231M
Sep 25, 2026$9.20$9.20$8.74$8.77515.63K
Sep 24, 2026$9.51$9.55$9.05$9.221.08M
Sep 23, 2026$10.58$10.58$9.50$9.56828.92K
Sep 22, 2026$10.60$10.99$10.531$10.57387.17K
Sep 21, 2026$10.57$10.75$10.30$10.47359.56K
Sep 18, 2026$10.84$10.97$10.46$10.54972.34K
Sep 17, 2026$11.14$11.165$10.69$10.86384.01K
Sep 16, 2026$11.17$11.4124$10.87$10.98505K
Sep 15, 2026$10.77$11.29$10.51$11.17602.6K

Latest QTTB news

The latest Smart Investors Daily articles mentioning QTTB.

Stock researchCompany · Overview

QTTB research

Overview

Company profile and research snapshot.

Company profile

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$63.83
Implied upside
—
Analysts
—
QTTB recent ratings
DateFirmRatingTarget
Oct 12, 2026Leerink PartnersOutperform—
Sep 28, 2026JefferiesBuy—
Aug 24, 2026Morgan StanleyOverweight—
Jul 28, 2026HC Wainwright & Co.Buy—
Jul 13, 2026OppenheimerOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA. These results were presented across a late-breaking oral and poster presentation at th

Benzinga · Sep 30, 2026

Q32 Bio Announces Additional 36-Week Results And Initial Findings From The 16-Week Off-Drug Period From Part B Of The SIGNAL-AA Phase 2A Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe AA; Clinically Meaningful Efficacy Data Observed On Primary And Key Secondary Endpoints At Week 36; Robust Durability, Including Maintenance And Deepening Of Response

These results were presented across a late-breaking oral and poster presentation at the European Academy of Dermatology and Venereology ("EADV") Congress 2026. Q32 Bio previously announced topline results from

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By